Immunogenicity and Safety Study of GSK Biologicals' Hib-MenC+Infanrix Penta Vaccines and NeisVac-C (Meningitis C Vaccine;Baxter)+GSK's Infanrix Hexa vs. Meningitec (Men. C Vaccine;Wyeth)+Infanrix Hexa in Healthy Infants (2,4,6 M).

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Hib-MenC+Infanrix Penta Vaccines and NeisVac-C (Meningitis C Vaccine;Baxter)+GSK's Infanrix Hexa vs. Meningitec (Men. C Vaccine;Wyeth)+Infanrix Hexa in Healthy Infants (2,4,6 M).

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Sep 2011 Actual completion date is September 2010 according to ClinicalTrials.gov (extension trial: NCT00322335).
    • 09 Sep 2011 Actual start date is May 2006 according to ClinicalTrials.gov (extension trial: NCT00322335).
    • 21 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top